Bank of Montreal’s Spero Therapeutics SPRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-79,500
Closed -$140K 4216
2024
Q1
$140K Buy
+79,500
New +$125K ﹤0.01% 3192
2022
Q4
Sell
-202,300
Closed -$415 4263
2022
Q3
$415 Buy
+202,300
New +$201K ﹤0.01% 2699
2021
Q2
Sell
-598
Closed -$8K 4800
2021
Q1
$8K Sell
598
-2,586
-81% -$45.5K ﹤0.01% 4471
2020
Q4
$51K Buy
3,184
+2,499
+365% +$39K ﹤0.01% 3928
2020
Q3
$8K Sell
685
-460
-40% -$5.44K ﹤0.01% 4240
2020
Q2
$16K Buy
+1,145
New +$12.9K ﹤0.01% 3957
2020
Q1
Sell
-1,357
Closed -$13K 4653
2019
Q4
$13K Buy
1,357
+401
+42% +$4.32K ﹤0.01% 4495
2019
Q3
$10K Buy
956
+70
+8% +$738 ﹤0.01% 4424
2019
Q2
$10K Buy
886
+860
+3,308% +$10.4K ﹤0.01% 4533
2019
Q1
$0 Sell
26
-104
-80% -$1.1K ﹤0.01% 4708
2018
Q4
$1K Buy
130
+71
+120% +$575 ﹤0.01% 4560
2018
Q3
$1K Buy
59
+12
+26% +$139 ﹤0.01% 4597
2018
Q2
$1K Buy
+47
New +$601 ﹤0.01% 4587

Other funds holding SPRO

Bank of Montreal's SPRO Position: Q2 2024 in Review

Bank of Montreal sold out of Spero Therapeutics (SPRO) in Q2 2024, closing a stake of 79,500 shares — an estimated $140K sold.

Bank of Montreal first reported a position in SPRO in Q2 2018 and held it in 13 quarters. The position peaked at $140K in Q1 2024. 48 funds tracked by Wall St. Rank hold SPRO as of Q2 2024.

  • Bank of Montreal reported no remaining Spero Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Bank of Montreal sold 79,500 Spero Therapeutics shares in Q2 2024, an estimated $140K.
  • Bank of Montreal first reported a position in Spero Therapeutics in Q2 2018 and held it in 13 quarters.
  • Bank of Montreal's Spero Therapeutics position peaked at $140K in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2024.

Based on Bank of Montreal's 13F filing for Q2 2024, filed 14 Aug 2024.